Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Poster

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…

CertaraJune 22, 2026

Poster

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Discover how active learning and Bayesian optimization improve virtual population generation for quantitative systems pharmacology…

CertaraJune 18, 2026

Poster

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Discover how a mechanistic quantitative systems pharmacology (QSP) model predicts mast cell inhibition and depletion…

CertaraJune 16, 2026

On-Demand Webinar

Building IND-Ready and Investor-Ready Development Programs

Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…

CertaraJune 15, 2026

Announcement

Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making

Certara was reappointed to a 4 year EMA and ECDC framework contract to generate real-world…

CertaraJune 11, 2026

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

CertaraJune 9, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Certara Services

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Mechanistic QSP Modeling to Support KIT Inhibitor Dose Selection, Biomarker Strategy, and Clinical Development

Building IND-Ready and Investor-Ready Development Programs

Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Newsletter sign up

Quick links

Solutions

Contact